anti cancer medicine

Fluoroblast Injection (Fluorouracil): Advanced Antimetabolite Therapy for Solid Tumors – Global Supply by Ernest Oncology In the core of modern oncology protocols, Fluoroblast Injection (containing the active ingredient Fluorouracil) remains one of the most critical and widely prescribed chemotherapy agents. As a pyrimidine antagonist, Fluoroblast has been a mainstay in cancer treatment for decades, serving as the backbone for legendary regimens like FOLFOX, FOLFIRI, and CMF. Its ability to inhibit DNA synthesis makes it indispensable for treating a broad spectrum of solid tumors across global healthcare systems. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We provide high-purity, GMP-certified Fluoroblast Injection to hospital networks and wholesalers in London (UK), the USA, Abu Dhabi (UAE), Australia, and South Africa, supported by validated 2026 global logistics. What is Fluoroblast Injection? (Mechanism & Clinical Role) Fluoroblast is a sterile, aqueous solution for intravenous administration, typically available in concentrations of 50 mg/mL (e.g., 250 mg, 500 mg, 1000 mg, and 5000 mg vials). As an antimetabolite, it mimics the building blocks of DNA to disrupt cancer cell growth. Primary Therapeutic Indications Colorectal Cancer: The primary component in adjuvant and metastatic treatment protocols. Breast Cancer: Frequently used in combination with cyclophosphamide and methotrexate (CMF regimen). Gastric & Pancreatic Cancer: A vital part of multi-drug regimens to improve survival outcomes in GI malignancies. Esophageal & Head and Neck Cancers: Often used as a radiosensitizer to enhance the efficacy of radiation therapy. Technical Product Profile: Fluoroblast (Fluorouracil) Feature Technical Specification Brand Name Fluoroblast Active Ingredient Fluorouracil (5-FU) Pharmacological Class Antimetabolite (Pyrimidine Analog) Available Strengths “250mg, 500mg, 1000mg, 2500mg, 5000mg Vials“ Manufacturer Leading Indian Oncology MNCs (WHO-GMP / USFDA Compliant) Dosage Form Solution for Intravenous Injection or Infusion Storage 15°C to 30°C; Protect from light; Do Not Refrigerate (to prevent precipitation) Mechanism of Action: Thymidylate Synthase Inhibition Fluoroblast exerts its cytotoxic effects by “tricking“ the cancer cell during the S-phase of the cell cycle: Metabolic Conversion: Once administered, the active ingredient is converted intracellularly into active metabolites (F-UMP, F-dUMP). Enzyme Blockade: It binds to the enzyme Thymidylate Synthase, which is essential for the production of thymidine (a DNA “brick“). DNA/RNA Disruption: By depriving the cell of thymidine, it causes “thymineless death.“ It also incorporates itself into RNA, further disrupting protein synthesis and triggering apoptosis. Clinical Administration & Safety Leucovorin Potentiation: Fluoroblast is often administered with Leucovorin (Folinic Acid), which binds with the active metabolite to the enzyme, making the treatment significantly more potent. Infusion Methods: It can be given as a rapid “bolus“ injection or as a continuous long-term infusion via a portable pump to maximize exposure to cancer cells. Safety Monitoring: Patients must be monitored for stomatitis (mouth sores), diarrhea, and “hand-foot syndrome.“ DPD Deficiency: Use with extreme caution in patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, as they cannot metabolize the drug normally. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s manufacturing prowess to stabilize the global supply of Fluoroblast. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Reliable supply to NHS Trusts and private oncology centers via MHRA-compliant channels. United States: Bulk supply for specialized pharmacies and hospital groups, supporting essential oncology care. Abu Dhabi & UAE: Fast-tracked export to the Middle East's growing oncology hubs, ensuring rapid availability for government tenders. Australia & South Africa: Strategic distribution to regional wholesalers, maintaining stable stock levels for national chemotherapy programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

5-FU Injection (Fluorouracil): The Core Antimetabolite for Advanced Oncology Regimens – Global Supply by Ernest Oncology In the landscape of 2026 oncology, 5-FU Injection (5-Fluorouracil) remains an absolute cornerstone of chemotherapy. As a potent pyrimidine antagonist, it is the backbone of the world’s most successful cancer treatment protocols, including FOLFOX, FOLFIRI, and FOLFIRINOX. Its ability to selectively inhibit the synthesis of DNA and RNA makes it indispensable for treating a vast array of solid tumors across global healthcare systems. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We provide high-purity, GMP-certified 5-FU Injection to hospital networks and wholesalers in London (UK), the USA, Abu Dhabi (UAE), Australia, and South Africa, supported by validated cold-chain logistics. What is 5-FU Injection? (Mechanism & Clinical Role) 5-FU is a sterile, aqueous solution for intravenous administration, typically available in strengths of 250 mg, 500 mg, 1000 mg, 2500 mg, and 5000 mg Vials (50 mg/mL concentration). It is classified as an antimetabolite, specifically a fluorinated pyrimidine. Primary Therapeutic Indications Colorectal Carcinoma: The primary component for both adjuvant and metastatic treatment of colon and rectal cancers. Breast Cancer: Frequently utilized in combination regimens such as CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil). Gastric & Pancreatic Cancer: A vital part of multi-drug protocols used to improve survival in gastrointestinal malignancies. Head and Neck Cancers: Often used as a radiosensitizer to increase the efficacy of concurrent radiation therapy. Dermatological Application: Occasionally used topically or via injection for certain pre-cancerous skin lesions and superficial basal cell carcinomas. Technical Product Profile: 5-FU (Fluorouracil) Feature Technical Specification Active Ingredient 5-Fluorouracil Pharmacological Class Antimetabolite (Pyrimidine Analog) Available Strengths “250mg, 500mg, 1000mg, 2500mg, 5000mg Vials“ Manufacturer Leading Indian Oncology MNCs (WHO-GMP / USFDA Compliant) Dosage Form Solution for IV Injection or Continuous Infusion Storage 15°C to 30°C; Protect from light; Do Not Refrigerate (to avoid crystal formation) Mechanism of Action: Thymineless Death 5-FU exerts its cytotoxic effects by mimicking the natural building blocks of the cell: Thymidylate Synthase Inhibition: 5-FU is converted into active metabolites (F-dUMP) that bind to the enzyme thymidylate synthase. This prevents the production of thymidine, which is essential for DNA replication. RNA Incorporation: Active metabolites (F-UTP) are mistakenly incorporated into RNA, disrupting normal protein synthesis and cellular function. S-Phase Specificity: It is most effective during the S-phase of the cell cycle, leading to “thymineless death“ in rapidly dividing malignant cells. Clinical Administration & Safety Leucovorin Potentiation: 5-FU is often administered with Leucovorin (Folinic Acid), which stabilizes the binding of 5-FU to the target enzyme, significantly increasing its therapeutic potency. Administration Methods: It can be delivered via rapid bolus injection or as a continuous 24–48 hour infusion using specialized infusion pumps to maintain constant therapeutic levels. Safety Monitoring: Common side effects include stomatitis, diarrhea, and Hand-Foot Syndrome. Clinicians must screen for DPD (Dihydropyrimidine Dehydrogenase) deficiency, as patients with this genetic trait cannot metabolize the drug safely. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology bridges the gap between high-quality Indian pharmaceutical manufacturing and global patient needs. We ensure that every batch of 5-FU reaches its destination with full documentation and regulatory compliance. United Kingdom & London: Reliable supply to NHS Trusts and private oncology clinics via MHRA-compliant supply chains. United States: Bulk procurement options for specialty pharmacies, hospital systems, and oncology centers. Abu Dhabi & UAE: Priority shipping to the Middle East's premier cancer treatment hubs and medical cities. Australia & South Africa: Strategic distribution to regional wholesalers, maintaining stable stock for national chemotherapy programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383

Fluorouracil Injection (5-FU): The Foundational Antimetabolite for Gastrointestinal and Breast Cancers – Global Supply by Ernest Oncology In the core of modern oncology protocols, Fluorouracil Injection (commonly known as 5-FU) remains one of the most critical and widely prescribed chemotherapy agents. As a pyrimidine antagonist, 5-FU has been a mainstay in cancer treatment for decades, serving as the backbone for legendary regimens like FOLFOX, FOLFIRI, and CMF. Its ability to inhibit DNA synthesis makes it indispensable for treating a broad spectrum of solid tumors. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We provide high-purity, GMP-certified Fluorouracil Injection to hospital networks and wholesalers in London (UK), the USA, Abu Dhabi (UAE), Australia, and South Africa, supported by validated 2026 global logistics. What is Fluorouracil Injection? (Mechanism & Clinical Role) Fluorouracil is a sterile, aqueous solution for intravenous administration, typically available in concentrations of 50 mg/mL (e.g., 250 mg, 500 mg, 1000 mg, and 5000 mg vials). As an antimetabolite, it mimics the building blocks of DNA to disrupt cancer cell growth. Primary Therapeutic Indications Colorectal Cancer: The primary component in adjuvant and metastatic treatment protocols. Breast Cancer: Frequently used in combination with cyclophosphamide and methotrexate (CMF regimen). Gastric & Pancreatic Cancer: A vital part of multi-drug regimens to improve survival outcomes in GI malignancies. Esophageal & Head and Neck Cancers: Often used as a radiosensitizer to enhance the efficacy of radiation therapy. Technical Product Profile: Fluorouracil (5-FU) Feature Technical Specification Active Ingredient Fluorouracil Pharmacological Class Antimetabolite (Pyrimidine Analog) Available Strengths “250mg, 500mg, 1000mg, 2500mg, 5000mg Vials“ Manufacturer Leading Indian Oncology MNCs (GMP / USFDA Compliant) Dosage Form Solution for Intravenous Injection or Infusion Storage 15°C to 30°C; Protect from light; Do Not Refrigerate (to prevent precipitation) Mechanism of Action: Thymidylate Synthase Inhibition Fluorouracil exerts its cytotoxic effects by “tricking“ the cancer cell during the S-phase of the cell cycle: Metabolic Conversion: Once administered, 5-FU is converted intracellularly into active metabolites (F-UMP, F-dUMP). Enzyme Blockade: It binds to the enzyme Thymidylate Synthase, which is essential for the production of thymidine (a DNA “brick“). DNA/RNA Disruption: By depriving the cell of thymidine, it causes “thymineless death.“ It also incorporates itself into RNA, further disrupting protein synthesis and triggering apoptosis. Clinical Administration & Safety Leucovorin Potentiation: 5-FU is often administered with Leucovorin (Folinic Acid), which binds with 5-FU to the enzyme, making the treatment significantly more potent. Infusion Methods: It can be given as a rapid “bolus“ injection or as a continuous long-term infusion via a portable pump to maximize exposure to cancer cells. Safety Monitoring: Patients must be monitored for stomatitis (mouth sores), diarrhea, and “hand-foot syndrome“ (redness/peeling of palms and soles). DPD Deficiency: Use with extreme caution in patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, as they cannot metabolize the drug normally. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s manufacturing prowess to stabilize the global supply of 5-FU. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Reliable supply to NHS Trusts and private oncology centers via MHRA-compliant channels. United States: Bulk supply for specialized pharmacies and hospital groups, supporting essential oncology care. Abu Dhabi & UAE: Fast-tracked export to the Middle East's growing oncology hubs, ensuring rapid availability for government tenders. Australia & South Africa: Strategic distribution to regional wholesalers, maintaining stable stock levels for national chemotherapy programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Oxaliplatin Injection: The Advanced Platinum Standard for Gastrointestinal Malignancies – Global Supply by Ernest Oncology In the intensive landscape of 2026 clinical oncology, Oxaliplatin Injection remains a cornerstone therapeutic for the treatment of colorectal and other gastrointestinal cancers. As a third-generation platinum-based antineoplastic, Oxaliplatin offers a unique diaminocyclohexane (DACH) carrier group that allows it to overcome resistance mechanisms that often hinder earlier platinum drugs like Cisplatin or Carboplatin. Its role in modern oncology is non-negotiable, particularly within the landmark FOLFOX and FOLFIRINOX regimens. What is Oxaliplatin Injection? (Mechanism & Clinical Role) Oxaliplatin is a sterile, aqueous solution for intravenous infusion, typically available in strengths of 50 mg, 100 mg, and 200 mg Vials. Unlike its predecessors, it exhibits a distinct spectrum of activity and a manageable toxicity profile, making it a preferred choice for combination therapies. Primary Therapeutic Indications Adjuvant Treatment of Colon Cancer: Indicated for stage III (Dukes’ C) colon cancer in patients who have undergone complete resection of the primary tumor. Metastatic Colorectal Cancer (mCRC): Used as a first-line or subsequent therapy for metastatic disease, often in combination with 5-fluorouracil (5-FU) and leucovorin. Advanced Gastric Cancer: Frequently utilized in aggressive multi-agent protocols to improve survival outcomes in gastric and gastroesophageal junction adenocarcinomas. Pancreatic Cancer: A critical component of the FOLFIRINOX regimen for patients with metastatic or locally advanced pancreatic adenocarcinoma. Technical Product Profile: Oxaliplatin Feature Technical Specification Active Ingredient Oxaliplatin Pharmacological Class Third-Generation Platinum Antineoplastic Available Strengths “50 mg / 10 mL, 100 mg / 20 mL, 200 mg / 40 mL“ Manufacturer Leading Indian Oncology MNCs (GMP / USFDA Compliant) Dosage Form Concentrated Solution or Lyophilized Powder for IV Infusion Storage 20°C to 25°C; Protect from light; Do Not Freeze Mechanism of Action: DNA Cross-linking Oxaliplatin exerts its cytotoxic effect by disrupting the DNA of rapidly dividing cancer cells: Activation: Once inside the cell, it undergoes non-enzymatic conversion to reactive platinum species. DACH Carrier: The bulky diaminocyclohexane (DACH) ring prevents DNA repair enzymes from fixing the damage, ensuring the drug remains effective against resistant cell lines. Structural Disruption: It forms reactive platinum complexes that bind to DNA, creating intra-strand and inter-strand cross-links, which inhibit DNA replication and transcription, triggering programmed cell death (apoptosis). Clinical Administration & Safety Incompatibility with Saline: Oxaliplatin is strictly incompatible with alkaline solutions or those containing chloride (like Normal Saline). It must be diluted only with 5% Dextrose/Glucose. Neurotoxicity Management: A unique side effect is cold-induced peripheral neuropathy. Patients are advised to avoid cold drinks and exposure to cold air or surfaces for several days post-infusion. Nephrologic Profile: Unlike Cisplatin, Oxaliplatin has a significantly lower risk of kidney damage (nephrotoxicity) and does not require extensive pre-hydration. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology bridges the gap between high-quality Indian pharmaceutical manufacturing and global patient needs. We ensure that every batch of Oxaliplatin reaches its destination with full documentation and strict temperature control. United Kingdom & London: Seamless supply to NHS Trusts and private oncology clinics in London via MHRA-compliant channels. United States: Reliable bulk procurement for specialized pharmacies, hospital systems, and oncology centers. Abu Dhabi & UAE: Priority shipping to the Middle East's premier cancer treatment hubs and medical cities. Australia & South Africa: Strategic distribution to regional wholesalers, ensuring availability for national gastrointestinal cancer programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Eloxatin Injection (Oxaliplatin): The Advanced Platinum Standard for Colorectal Cancer – Global Supply by Ernest Oncology In the intensive landscape of clinical oncology, Eloxatin Injection (the brand name for Oxaliplatin) stands as a critical therapeutic for gastrointestinal malignancies. As a third-generation platinum-based antineoplastic, Eloxatin offers a unique diaminocyclohexane (DACH) carrier group that allows it to overcome resistance mechanisms that often hinder earlier platinum drugs like Cisplatin. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Eloxatin Injection to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via validated pharmaceutical cold-chain logistics. What is Eloxatin Injection? (Mechanism & Clinical Role) Eloxatin is a sterile, aqueous solution for intravenous infusion, typically available in strengths of 50 mg and 100 mg Vials (5 mg/mL concentration). It is the foundational component of the landmark FOLFOX regimen (Fluorouracil, Leucovorin, and Oxaliplatin). Primary Therapeutic Indications Adjuvant Treatment of Colon Cancer: Indicated for patients with stage III colon cancer who have undergone complete resection of the primary tumor. Metastatic Colorectal Cancer (mCRC): Used as a first-line or subsequent therapy for patients with metastatic disease, often in combination with 5-FU/LV. Advanced Gastric & Pancreatic Cancer: Frequently utilized in aggressive multi-agent protocols like FOLFIRINOX for gastrointestinal malignancies. Esophageal Cancer: Often part of neoadjuvant or metastatic treatment plans. Technical Product Profile: Eloxatin (Oxaliplatin) Feature Technical Specification Brand Name Eloxatin Active Ingredient Oxaliplatin Pharmacological Class Third-Generation Platinum Antineoplastic Available Strengths “50 mg / 10 mL, 100 mg / 20 mL“ Manufacturer Sanofi / Leading WHO-GMP Indian Partners Dosage Form Solution for IV Infusion Storage 20°C to 25°C; Protect from light; Do Not Freeze Mechanism of Action: Overcoming Drug Resistance Eloxatin exerts its cytotoxic effect by disrupting the DNA of rapidly dividing cancer cells: DACH Complex: The bulky diaminocyclohexane (DACH) ring prevents DNA repair enzymes from fixing the damage caused by the platinum, making it effective where other platinum drugs fail. DNA Cross-linking: It forms reactive platinum complexes that bind to DNA, creating intra-strand and inter-strand cross-links. Cytotoxicity: These cross-links inhibit DNA replication and transcription, triggering programmed cell death (apoptosis) in malignant cells. Clinical Administration & Safety Incompatibility with Saline: Eloxatin is strictly incompatible with alkaline solutions or those containing chloride (like Normal Saline). It must be diluted only with 5% Dextrose/Glucose. Neurotoxicity Management: A unique side effect is cold-induced peripheral neuropathy. Patients are advised to avoid cold drinks, ice, and cold air for several days post-infusion. Nephrologic Profile: Unlike Cisplatin, Eloxatin does not require extensive pre-hydration because it has a significantly lower risk of kidney damage (nephrotoxicity). Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s world-class manufacturing to stabilize the global supply of Eloxatin. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Seamless supply to NHS Trusts and private oncology clinics in London via MHRA-compliant channels. United States: Reliable bulk procurement for specialized pharmacies, hospital systems, and oncology centers. Abu Dhabi & UAE: Priority shipping to the Middle East's premier cancer treatment hubs and medical cities. Australia & South Africa: Strategic distribution to regional wholesalers, ensuring availability for national gastrointestinal cancer programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Oxiplat Injection (Oxaliplatin): The Advanced Platinum Standard for Colorectal Cancer – Global Supply by Ernest Oncology In the evolving landscape of 2026 oncology, Oxiplat Injection (containing the active ingredient Oxaliplatin) stands as a critical therapeutic for gastrointestinal malignancies. As a third-generation platinum-based antineoplastic, Oxiplat offers a unique diaminocyclohexane (DACH) carrier group that allows it to overcome resistance mechanisms that often hinder earlier platinum drugs like Cisplatin. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Oxiplat Injection to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via validated pharmaceutical cold-chain logistics. What is Oxiplat Injection? (Mechanism & Clinical Indications) Oxiplat is a sterile, aqueous solution for intravenous infusion, typically available in strengths of 50 mg and 100 mg Vials. It is most frequently utilized in the landmark FOLFOX regimen (Fluorouracil, Leucovorin, and Oxaliplatin). Primary Therapeutic Indications Colorectal Cancer: Indicated for the adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. Metastatic Colorectal Cancer: Used as a first-line or subsequent therapy for patients with metastatic disease. Gastric & Pancreatic Cancer: Increasingly used in multi-agent protocols (like FOLFIRINOX) for advanced gastrointestinal malignancies. Esophageal Cancer: Often part of neoadjuvant or metastatic treatment plans. Technical Product Profile: Oxiplat (Oxaliplatin) Feature Technical Specification Active Ingredient Oxaliplatin Pharmacological Class Third-Generation Platinum Antineoplastic Available Strengths “50 mg / 10 mL, 100 mg / 20 mL“ Manufacturer Leading Indian Oncology MNCs (WHO-GMP / USFDA Compliant) Dosage Form Concentrated Solution or Lyophilized Powder for IV Infusion Storage 20°C to 25°C; Protect from light; Do Not Freeze Mechanism of Action: Overcoming Drug Resistance Oxiplat exerts its cytotoxic effect by disrupting the DNA of rapidly dividing cancer cells: DACH Complex: The bulky diaminocyclohexane (DACH) ring prevents DNA repair enzymes from fixing the damage caused by the platinum. DNA Cross-linking: It forms reactive platinum complexes that bind to DNA, creating intra-strand and inter-strand cross-links. Apoptosis: These cross-links inhibit DNA replication and transcription, triggering programmed cell death in malignant cells. Clinical Administration & Safety Glucose 5% Only: Oxiplat is incompatible with alkaline solutions or those containing chloride (like Normal Saline). It must be diluted only with 5% Dextrose/Glucose. Neurotoxicity Management: A unique side effect of Oxiplat is cold-induced peripheral neuropathy. Patients are advised to avoid cold drinks and cold air for several days post-infusion. No Nephrotoxicity: Unlike Cisplatin, Oxiplat does not require extensive pre-hydration as it has a significantly lower risk of kidney damage. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s manufacturing excellence to stabilize the global supply of Oxiplat. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Seamless supply to NHS Trusts and private oncology clinics in London via MHRA-compliant channels. United States: Reliable bulk procurement for specialized pharmacies and hospital systems. Abu Dhabi & UAE: Priority shipping to the Middle East's premier cancer treatment hubs. Australia & South Africa: Strategic distribution to regional wholesalers, ensuring availability for national gastrointestinal cancer programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Carboplatin Injection: Advanced Platinum-Based Therapy for Solid Tumors – Global Supply by Ernest Oncology In modern oncology, Carboplatin Injection is a foundational therapeutic agent used across a wide spectrum of malignancies. As a second-generation platinum compound, Carboplatin provides a highly effective mechanism for disrupting cancer cell division while offering a more manageable safety profile than earlier platinum therapies. It remains a critical component of both curative and palliative chemotherapy regimens globally. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Carboplatin Injection to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via validated pharmaceutical logistics. What is Carboplatin Injection? (Mechanism & Clinical Indications) Carboplatin is a sterile, aqueous solution for intravenous infusion, typically available in strengths of 150 mg, 450 mg, and 600 mg Vials (10 mg/mL concentration). It belongs to the group of medicines known as platinum-containing antineoplastics. Primary Therapeutic Indications Ovarian Carcinoma: Widely used as a first-line treatment for advanced ovarian cancer of epithelial origin. Small Cell Lung Cancer (SCLC): A cornerstone in combination therapy for patients with extensive or limited-stage SCLC. Non-Small Cell Lung Cancer (NSCLC): Often paired with paclitaxel or gemcitabine for advanced NSCLC protocols. Head and Neck Squamous Cell Carcinoma: Frequently utilized in multi-modal treatment plans. Other Malignancies: Effective in treating certain types of Breast, Bladder, and Cervical cancers, as well as Brain Tumors in pediatric and adult populations. Technical Product Profile: Carboplatin 10 mg/mL Solution Feature Technical Specification Active Ingredient Carboplatin Pharmacological Class Platinum-Based Antineoplastic Agent Available Strengths “150 mg / 15 mL, 450 mg / 45 mL, 600 mg / 60 mL“ Manufacturer Leading Indian Oncology MNCs (WHO-GMP / USFDA Compliant) Dosage Form Liquid Solution for IV Infusion Storage 15°C to 30°C; Protect from light; Do Not Freeze Mechanism of Action: DNA Adduct Formation Carboplatin exerts its cytotoxic effect by disrupting the cellular blueprint of cancer cells: Activation: Once inside the cell, Carboplatin undergoes a chemical change to form a reactive platinum species. DNA Binding: These species bind to DNA strands, creating inter-strand and intra-strand DNA cross-links. Cytotoxicity: These cross-links inhibit DNA replication and transcription, forcing the cancer cell to undergo programmed cell death (apoptosis). Clinical Administration & Dosing Precision Calvert Formula: Unlike many chemotherapies, Carboplatin dosing is uniquely calculated using the Calvert Formula, which accounts for a patient's renal function (GFR) to achieve a targeted Area Under the Curve (AUC). Hematologic Safety: The primary dose-limiting toxicity is myelosuppression. Regular CBC (Complete Blood Count) monitoring is mandatory. Outpatient Convenience: Because Carboplatin requires less intensive pre-hydration than Cisplatin, it is frequently administered in outpatient oncology settings. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology bridges the gap between high-quality Indian pharmaceutical manufacturing and global patient needs. We ensure that every batch of Carboplatin reaches its destination with full documentation and regulatory compliance. United Kingdom & London: Direct supply to NHS Trusts and private oncology networks via MHRA-compliant supply chains. United States: Reliable bulk procurement options for specialized pharmacies, hospital systems, and clinical research. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s leading cancer research and treatment centers. Australia & South Africa: Strategic distribution to regional wholesalers, supporting national health tenders and private hospital groups. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Paraplatin Injection (Carboplatin): High-Efficacy Platinum Therapy for Solid Tumors – Global Supply by Ernest Oncology In the intensive field of oncology, Paraplatin Injection (the brand name for Carboplatin) remains a foundational therapeutic agent. As a second-generation platinum-based antineoplastic, Paraplatin is globally recognized for its efficacy in treating various cancers while offering a more favorable toxicity profile compared to its predecessor, Cisplatin. Its predictable pharmacokinetics make it a staple in both curative and palliative chemotherapy regimens. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Paraplatin Injection to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via validated pharmaceutical logistics. What is Paraplatin Injection? (Mechanism & Clinical Role) Paraplatin is a sterile, aqueous solution for intravenous infusion, typically available in strengths of 50mg, 150mg, 450mg, and 600mg Vials (10mg/mL concentration). It is a platinum coordination compound that interferes with the DNA of malignant cells. Primary Therapeutic Indications Ovarian Carcinoma: A gold-standard first-line treatment for advanced ovarian cancer, often used in combination with Paclitaxel. Lung Cancer: Extensively used in the treatment of Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). Head and Neck Cancers: Integral to multi-agent protocols for squamous cell carcinomas. Other Malignancies: Frequently utilized in treating Brain Tumors, Neuroblastoma, and specialized cases of Breast and Bladder cancers. Technical Product Profile: Paraplatin 10mg/mL Solution Feature Technical Specification Brand Name Paraplatin Active Ingredient Carboplatin Pharmacological Class Platinum-Based Antineoplastic Agent Available Strengths “50 mg, 150 mg, 450 mg, 600 mg Vials“ Manufacturer Leading Global Oncology MNCs / Indian GMP Partners Dosage Form Injectable Liquid Solution (IV Use Only) Storage 15°C to 30°C; Protect from light; Do Not Freeze Mechanism of Action: DNA Adduct Formation Paraplatin exerts its cytotoxic effect by disrupting the cellular blueprint of cancer cells: Activation: Once inside the cell, Paraplatin undergoes activation to bind with DNA. Cross-Linking: It creates intra-strand and inter-strand DNA cross-links, effectively “stapling“ the DNA strands together. Apoptosis: This structural damage prevents DNA replication and transcription, forcing the cancer cell into programmed cell death (apoptosis). Clinical Administration & Dosing Precision Calvert Formula: Paraplatin dosing is uniquely calculated using the Calvert Formula, which accounts for a patient's renal function (GFR) to achieve a targeted Area Under the Curve (AUC), ensuring maximum efficacy with minimized toxicity. Safety Profile: Compared to Cisplatin, Paraplatin significantly reduces the risk of nephrotoxicity (kidney damage) and ototoxicity (hearing loss), though it requires careful monitoring for myelosuppression (bone marrow activity). Administration: Typically administered as an IV infusion over 15 to 60 minutes, often in an outpatient oncology setting. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s world-class pharmaceutical manufacturing to stabilize the global supply of Paraplatin. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Supporting NHS hospital trusts and private oncology centers in London and across the UK via MHRA-compliant supply chains. United States: Providing reliable bulk procurement for specialized pharmacies, hospital systems, and clinical research centers. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s leading cancer care facilities and medical hubs. Australia & South Africa: Strategic distribution to regional wholesalers and health departments, maintaining stable stock for national chemotherapy programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty oncology and life-saving medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Carboplat Injection (Carboplatin): Advanced Platinum-Based Therapy for Solid Tumors – Global Supply by Ernest Oncology In modern oncology, Carboplat Injection (containing the active ingredient Carboplatin) is a cornerstone of chemotherapy for various malignancies. As a second-generation platinum compound, Carboplat offers a therapeutic profile similar to Cisplatin but with a significantly improved safety margin, particularly regarding renal and ototoxicity. It remains a foundational treatment in both curative and palliative settings worldwide. Ernest Oncology, the specialized oncology wing of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We provide high-purity, GMP-certified Carboplat Injection to healthcare providers and wholesalers in London (UK), the USA, Abu Dhabi (UAE), Australia, and South Africa, utilizing validated 2026 global cold-chain logistics. What is Carboplat Injection? (Mechanism & Clinical Indications) Carboplat is a sterile, aqueous solution for intravenous infusion, typically available in strengths of 150mg, 450mg, and 600mg Vials (10mg/mL concentration). It is a platinum-coordination compound that interferes with the growth of cancer cells. Primary Therapeutic Indications Ovarian Carcinoma: Used as a first-line treatment in combination with other agents for advanced ovarian cancer. Lung Cancer: Highly effective in the treatment of both Small Cell Lung Cancer (SCLC) and Non-Small Cell Lung Cancer (NSCLC). Head and Neck Cancers: Frequently used in multi-modal treatment plans for squamous cell carcinomas. Other Malignancies: Often utilized in treating Brain Tumors, Neuroblastoma, and certain types of Breast and Bladder cancers. Technical Product Profile: Carboplat 10mg/mL Solution Feature Technical Specification Active Ingredient Carboplatin Pharmacological Class Platinum-Based Antineoplastic Agent Available Strengths “150 mg / 15 mL, 450 mg / 45 mL, 600 mg / 60 mL“ Manufacturer Leading Indian Oncology MNCs (GMP / USFDA Compliant) Dosage Form Liquid Solution for IV Infusion Storage Store at 15°C to 30°C; Protect from light; Do Not Freeze Mechanism of Action: DNA Adduct Formation Carboplat works by inducing DNA damage in cancer cells: Activation: It undergoes intracellular activation to produce reactive platinum species. DNA Binding: These species bind to DNA, creating inter-strand and intra-strand cross-links. Cytotoxicity: The cross-linking inhibits DNA synthesis and transcription, triggering cell cycle arrest and apoptosis (programmed cell death) in rapidly dividing malignant cells. Clinical Administration & Dosing Calvert Formula: Unlike many chemotherapies, Carboplat dosing is often calculated based on a patient’s renal function (GFR) using the Calvert Formula to achieve a target “Area Under the Curve“ (AUC). Hematologic Monitoring: The primary dose-limiting toxicity is myelosuppression (reduction in blood counts). Regular CBC (Complete Blood Count) monitoring is essential. Ease of Administration: Carboplat generally requires less intensive pre-hydration than Cisplatin, making it more suitable for outpatient settings. Global Supply Chain Excellence: London, USA, UAE, Australia, & South Africa Ernest Oncology bridges the gap between high-quality Indian pharmaceutical manufacturing and global patient needs. We ensure that every batch of Carboplat reaches its destination with full documentation and regulatory compliance. United Kingdom & London: Direct supply to NHS and private oncology networks in London and across the UK. United States: Reliable bulk procurement options for specialty pharmacies and hospital systems. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s leading cancer research and treatment centers. Australia & South Africa: Strategic distribution to regional wholesalers, supporting national health tenders and private hospital groups. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Ciplatin Injection (Cisplatin): The Platinum-Based Gold Standard for Advanced Malignancies – Global Supply by Ernest Oncology In the intensive landscape of clinical oncology, Ciplatin Injection (containing the active ingredient Cisplatin) remains one of the most effective and widely utilized antineoplastic agents. Often referred to as the “penicillin of cancer drugs,“ this platinum-based therapeutic is a cornerstone in both curative and palliative treatment protocols for solid tumors. Its ability to disrupt DNA replication makes it indispensable in multi-drug chemotherapy regimens. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We provide high-purity, GMP-certified Ciplatin Injection to hospital networks and wholesalers in London (UK), the USA, Abu Dhabi (UAE), Australia, and South Africa, backed by 2026-standard global logistics. What is Ciplatin Injection? (Mechanism & Clinical Role) Ciplatin is a sterile, aqueous solution for intravenous infusion, typically available in strengths of 10mg, 50mg, and 100mg Vials (1mg/mL concentration). As a bifunctional alkylating-like agent, it is classified as a platinum-coordination compound. Primary Therapeutic Indications Testicular Cancer: Historically the first cancer successfully treated with platinum agents; it remains a first-line treatment for metastatic germ cell tumors. Ovarian Carcinoma: Used as secondary therapy for patients refractory to standard chemotherapy or in combination with other agents for advanced-stage cases. Bladder Cancer: Indicated for patients with locally advanced or metastatic transitional cell carcinoma of the bladder who are no longer candidates for local therapy. Other Malignancies: Frequently used in protocols for Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma, and Cervical Cancer. Technical Product Profile: Ciplatin 1mg/mL Solution Feature Technical Specification Brand Name Ciplatin Active Ingredient Cisplatin (cis-diamminedichloroplatinum) Pharmacological Class Platinum-Based Antineoplastic / Alkylating Agent Available Strengths “10 mg / 10 mL, 50 mg / 50 mL, 100 mg / 100 mL“ Manufacturer Leading Indian Oncology MNCs (WHO-GMP / USFDA Compliant) Storage Room Temperature (15°C to 25°C); Protect from light; Do Not Refrigerate Clinical Administration & Safety Hydration Protocol: Significant pre-treatment and post-treatment hydration (usually with normal saline) is mandatory to ensure a urine output of at least 100 mL/hour, minimizing the risk of nephrotoxicity. Anti-Emetic Therapy: Due to its high emetogenic potential, modern protocols include aggressive anti-emetic premedication (e.g., 5-HT3 receptor antagonists). Monitoring: Clinicians must monitor Serum Creatinine, BUN, and Magnesium levels before each cycle. Baseline and periodic audiometric testing is required to monitor for cumulative ototoxicity (hearing loss). Incompatibility: Ciplatin reacts with aluminum; therefore, administration sets containing aluminum components must not be used. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s manufacturing prowess to stabilize the global supply of Ciplatin. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Seamless supply to NHS Trusts and London’s private oncology clinics via MHRA-compliant channels. United States: Reliable bulk supply for specialized pharmacies and hospital groups, supporting cost-effective oncology care. Abu Dhabi & UAE: Priority shipping to the Middle East's growing oncology hubs, ensuring rapid availability for government tenders. Australia & South Africa: Strategic distribution to regional wholesalers and health departments, maintaining stable stock levels for critical chemotherapy programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Platinol Injection (Cisplatin): The Platinum-Based Gold Standard for Advanced Malignancies – Global Supply by Ernest Oncology In the intensive landscape of clinical oncology, Platinol Injection (the brand name for Cisplatin) remains one of the most effective and widely utilized antineoplastic agents. Often referred to as the “penicillin of cancer drugs,“ this platinum-based therapeutic is a cornerstone in both curative and palliative treatment protocols for solid tumors. Its ability to disrupt DNA replication makes it indispensable in multi-drug chemotherapy regimens. Ernest Oncology, the specialized oncology division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We provide high-purity, GMP-certified Platinol Injection to hospital networks and wholesalers in London (UK), the USA, Abu Dhabi (UAE), Australia, and South Africa, backed by 2026-standard global logistics. What is Platinol Injection? (Mechanism & Clinical Role) Platinol is a sterile, aqueous solution for intravenous infusion, typically available in strengths of 10mg, 50mg, and 100mg Vials (1mg/mL concentration). As a bifunctional alkylating-like agent, it is classified as a platinum-coordination compound. Primary Therapeutic Indications Testicular Cancer: Historically the first cancer successfully treated with Platinol; it remains a first-line treatment for metastatic germ cell tumors. Ovarian Carcinoma: Used as secondary therapy for patients refractory to standard chemotherapy or in combination with other agents for advanced-stage cases. Bladder Cancer: Indicated for patients with locally advanced or metastatic transitional cell carcinoma of the bladder who are no longer candidates for local therapy. Other Malignancies: Frequently used in protocols for Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma, and Cervical Cancer. Technical Product Profile: Platinol 1mg/mL Solution Feature Technical Specification Brand Name Platinol / Platinol-AQ Active Ingredient Cisplatin (cis-diamminedichloroplatinum) Pharmacological Class Platinum-Based Antineoplastic / Alkylating Agent Available Strengths “10 mg / 10 mL, 50 mg / 50 mL, 100 mg / 100 mL“ Manufacturer Leading Indian Oncology MNCs (WHO-GMP / USFDA Compliant) Storage Room Temperature (15°C to 25°C); Protect from light; Do Not Refrigerate Mechanism of Action: DNA Cross-Linking Platinol exerts its cytotoxic effects by targeting the DNA within rapidly dividing cancer cells: Activation: Once inside the cell, chloride ligands are displaced by water molecules, forming a positively charged platinum complex. Adduct Formation: These complexes bind to DNA bases, primarily the N7 position of guanine. Structural Disruption: It creates intra-strand and inter-strand cross-links, which bend the DNA and prevent replication, transcription, and repair. This eventually triggers programmed cell death (apoptosis). Clinical Administration & Safety Hydration Protocol: Significant pre-treatment and post-treatment hydration (usually with normal saline) is mandatory to ensure a urine output of at least 100 mL/hour, minimizing the risk of nephrotoxicity. Anti-Emetic Therapy: Due to its high emetogenic potential, modern protocols include aggressive anti-emetic premedication (e.g., 5-HT3 receptor antagonists). Monitoring: Clinicians must monitor Serum Creatinine, BUN, and Magnesium levels before each cycle. Baseline and periodic audiometric testing is required to monitor for cumulative ototoxicity (hearing loss). Incompatibility: Platinol reacts with aluminum; therefore, administration sets containing aluminum components must not be used. Global Supply Chain: London, USA, UAE, Australia, & South Africa United Kingdom & London: Seamless supply to NHS Trusts and London’s private oncology clinics via MHRA-compliant channels. United States: Reliable bulk supply for specialized pharmacies and hospital groups, supporting cost-effective oncology care. Abu Dhabi & UAE: Priority shipping to the Middle East's growing oncology hubs, ensuring rapid availability for government tenders. Australia & South Africa: Strategic distribution to regional wholesalers and health departments, maintaining stable stock levels for critical chemotherapy programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Cisplatin Injection: The Platinum-Based Gold Standard for Advanced Malignancies – Global Supply by Ernest Oncology In the intensive landscape of clinical oncology, Cisplatin Injection remains one of the most effective and widely utilized antineoplastic agents. Often referred to as the “penicillin of cancer drugs,“ this platinum-based therapeutic is a cornerstone in both curative and palliative treatment protocols for solid tumors. Its ability to disrupt DNA replication makes it indispensable in multi-drug chemotherapy regimens. What is Cisplatin Injection? Cisplatin Injection is a sterile, aqueous solution for intravenous infusion, typically available in strengths of 10mg, 50mg, and 100mg Vials (1mg/mL concentration). As a bifunctional alkylating-like agent, it is classified as a platinum-coordination compound. Primary Therapeutic Indications Testicular Cancer: Historically the first cancer successfully treated with Cisplatin; it remains a first-line treatment for metastatic germ cell tumors. Ovarian Carcinoma: Used as secondary therapy for patients refractory to standard chemotherapy or in combination with other agents for advanced-stage cases. Bladder Cancer: Indicated for patients with locally advanced or metastatic transitional cell carcinoma of the bladder who are no longer candidates for local therapy. Other Malignancies: Frequently used “off-label“ or in clinical trials for Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma, and Cervical Cancer. Technical Product Profile: Cisplatin 1mg/mL Solution Feature Technical Specification Active Ingredient Cisplatin (cis-diamminedichloroplatinum) Pharmacological Class Platinum-Based Antineoplastic / Alkylating Agent Available Strengths “10 mg / 10 mL, 50 mg / 50 mL, 100 mg / 100 mL“ Manufacturer Leading Indian Oncology MNCs (WHO-GMP / USFDA Compliant) Dosage Form Injectable Liquid Solution (IV Use Only) Storage Room Temperature (15°C to 25°C); Protect from light; Do Not Refrigerate Mechanism of Action: DNA Cross-Linking Cisplatin exerts its cytotoxic effects by targeting the DNA within rapidly dividing cancer cells: Activation: Once inside the cell, chloride ligands are displaced by water molecules, forming a positively charged platinum complex. Adduct Formation: These complexes bind to DNA bases, primarily the N7 position of guanine. Structural Disruption: It creates intra-strand and inter-strand cross-links, which bend the DNA and prevent replication, transcription, and repair. This eventually triggers programmed cell death (apoptosis). Clinical Administration & Safety Hydration Protocol: Significant pre-treatment and post-treatment hydration (usually with normal saline) is mandatory to ensure a urine output of at least 100 mL/hour, minimizing the risk of nephrotoxicity. Anti-Emetic Therapy: Due to its high emetogenic potential, modern protocols include aggressive anti-emetic premedication Monitoring: Clinicians must monitor Serum Creatinine, BUN, and Magnesium levels before each cycle. Baseline and periodic audiometric testing is required to monitor for cumulative ototoxicity (hearing loss). Incompatibility: Cisplatin reacts with aluminum; therefore, administration sets containing aluminum components must not be used. Global Supply Chain: London, USA, UAE, Australia, & South Africa Ernest Oncology leverages India’s manufacturing prowess to stabilize the global supply of Cisplatin. We ensure that B2B buyers receive products that meet the stringent 2026 quality benchmarks of international regulatory bodies. United Kingdom & London: Seamless supply to NHS Trusts and London’s private oncology clinics via MHRA-compliant channels. United States: Reliable bulk supply for specialized pharmacies and hospital groups, supporting cost-effective oncology care. Abu Dhabi & UAE: Priority shipping to the Middle East's growing oncology hubs, ensuring rapid availability for government tenders. Australia & South Africa: Strategic distribution to regional wholesalers and health departments, maintaining stable stock levels for critical chemotherapy programs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader for the bulk procurement of high-quality oncology injectables. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383